{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:35:46Z","timestamp":1790627746935,"version":"4.1.0"},"reference-count":251,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01587-0","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:45:59Z","timestamp":1763390759000},"page":"1743-1783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease"],"prefix":"10.1007","volume":"64","author":[{"given":"Puja","family":"Dhungana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-9746","authenticated-orcid":false,"given":"Tony K. L.","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"13","key":"1587_CR1","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294\u2013304.","journal-title":"JAMA"},{"key":"1587_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13020142","author":"YJ Lim","year":"2021","unstructured":"Lim YJ,\u00a0 Sidor NA, Tonial NC, et al. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: mechanisms and therapeutic targets. Toxins (Basel). 2021;13(2):142.\u00a0https:\/\/doi.org\/10.3390\/toxins13020142.","journal-title":"Toxins (Basel)"},{"key":"1587_CR3","volume":"36","author":"MM Ali","year":"2024","unstructured":"Ali MM, Parveen S, Williams V, Dons R, Uwaifo GI, et al. Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD). J Clin Transl Endocrinol. 2024;36:100341.","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"1587_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12325-021-01927-z","volume":"39","author":"M Evans","year":"2022","unstructured":"Evans M, Lewis RD, Morgan AR, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33\u201343.","journal-title":"Adv Ther"},{"key":"1587_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2020.01.024","volume":"157","author":"T Nakanishi","year":"2020","unstructured":"Nakanishi T, Nanami M, Kuragano T. The pathogenesis of CKD complications; attack of dysregulated iron and phosphate metabolism. Free Radic Biol Med. 2020;157:55\u201362.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"1587_CR6","first-page":"335","volume":"45","author":"CLC Elorza","year":"2023","unstructured":"Elorza CLC, Santos Junior AD, Celeri E. Quality of life, depression and anxiety in children and adolescents with CKD and their primary caregivers. Braz J Nephrol. 2023;45(3):335\u201343.","journal-title":"Braz J Nephrol"},{"issue":"1","key":"1587_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14737167.2021.1854091","volume":"21","author":"H Hussien","year":"2021","unstructured":"Hussien H, Apetrii M, Covic A. Health-related quality of life in patients with chronic kidney disease. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):43\u201354.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"1587_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.ajkd.2020.11.026","volume":"78","author":"O Swartling","year":"2021","unstructured":"Swartling O, Rydell H, Stendahl M et al. CKD progression and mortality among men and women: a nationwide study in Sweden. Am J Kidney Dis. 2021;78(2):190-9.e1.","journal-title":"Am J Kidney Dis"},{"key":"1587_CR9","doi-asserted-by":"publisher","first-page":"1338025","DOI":"10.3389\/fimmu.2024.1338025","volume":"15","author":"L Gu","year":"2024","unstructured":"Gu L, Xia Z, Qing B, et al. Systemic inflammatory response index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001\u20132018). Front Immunol. 2024;15:1338025.","journal-title":"Front Immunol"},{"key":"1587_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9020052","author":"T Gryp","year":"2017","unstructured":"Gryp T, Vanholder R, Vaneechoutte M, et al. p-Cresyl sulfate. Toxins (Basel). 2017;9(2):52\u00a0https:\/\/doi.org\/10.3390\/toxins9020052.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"1587_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/ndt\/gfq818","volume":"26","author":"BK Meijers","year":"2011","unstructured":"Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant. 2011;26(3):759\u201361.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1587_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1124\/dmd.122.000967","volume":"51","author":"H Arakawa","year":"2023","unstructured":"Arakawa H, Kato Y. Emerging roles of uremic toxins and inflammatory cytokines in the alteration of hepatic drug disposition in patients with kidney dysfunction. Drug Metab Dispos. 2023;51(9):1127\u201335.","journal-title":"Drug Metab Dispos"},{"key":"1587_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14030177","author":"RSD Cunha","year":"2022","unstructured":"Cunha RSD, Azevedo CAB, Falconi CA, et al. The interplay between uremic toxins and albumin, membrane transporters and drug interaction. Toxins (Basel). 2022;14(3):177.\u00a0https:\/\/doi.org\/10.3390\/toxins14030177.","journal-title":"Toxins (Basel)"},{"issue":"4","key":"1587_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018438","volume":"6","author":"HA Mutsaers","year":"2011","unstructured":"Mutsaers HA, Heuvel LP, Ringens LH, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS ONE. 2011;6(4):e18438.","journal-title":"PLoS ONE"},{"issue":"11","key":"1587_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2215\/CJN.02440314","volume":"10","author":"SK Nigam","year":"2015","unstructured":"Nigam SK, Wu W, Bush KT, et al. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10(11):2039\u201349.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1587_CR16","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1002\/jps.22640","volume":"100","author":"M Reyes","year":"2011","unstructured":"Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011;100(9):3831\u201342.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1587_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yrtph.2013.10.006","volume":"68","author":"DA Volpe","year":"2014","unstructured":"Volpe DA, Tobin GA, Tavakkoli F, et al. Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regul Toxicol Pharmacol. 2014;68(2):297\u2013303.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"1587_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, et al. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85(3):522\u20138.","journal-title":"Kidney Int"},{"key":"1587_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16050227","author":"B Meijers","year":"2024","unstructured":"Meijers B, Zadora W, Lowenstein J. A historical perspective on uremia and uremic toxins. Toxins (Basel). 2024;16(5):227. https:\/\/doi.org\/10.3390\/toxins16050227.","journal-title":"Toxins (Basel)"},{"key":"1587_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123578","volume":"1215","author":"SR Fernandes","year":"2023","unstructured":"Fernandes SR, Meireles AN, Marques SS, et al. Sample preparation and chromatographic methods for the determination of protein-bound uremic retention solutes in human biological samples: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1215:123578.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1587_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108679","volume":"112","author":"JS Park","year":"2019","unstructured":"Park JS, Choi HI, Kim DH, et al. Alpha-lipoic acid attenuates p-cresyl sulfate-induced renal tubular injury through suppression of apoptosis and autophagy in human proximal tubular epithelial cells. Biomed Pharmacother. 2019;112:108679.","journal-title":"Biomed Pharmacother"},{"key":"1587_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060743","author":"AR Al-Dajani","year":"2024","unstructured":"Al-Dajani AR, Hou QK, Kiang TKL. Liquid chromatography-mass spectrometry analytical methods for the quantitation of p-cresol sulfate and indoxyl sulfate in human matrices: biological applications and diagnostic potentials. Pharmaceutics. 2024;16(6):743.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics16060743.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1587_CR23","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00216-012-6636-9","volume":"405","author":"J Boelaert","year":"2013","unstructured":"Boelaert J, Lynen F, Glorieux G, et al. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal Bioanal Chem. 2013;405(6):1937\u201347.","journal-title":"Anal Bioanal Chem"},{"issue":"4","key":"1587_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/ki.2012.448","volume":"83","author":"H Watanabe","year":"2013","unstructured":"Watanabe H, Miyamoto Y, Honda D, et al. P-cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013;83(4):582\u201392.","journal-title":"Kidney Int"},{"issue":"1","key":"1587_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ndt\/gft367","volume":"29","author":"J Poveda","year":"2014","unstructured":"Poveda J, Nino MD, Glorieux G, et al. P-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant. 2014;29(1):56\u201364.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1587_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/ki.2015.287","volume":"89","author":"YJ Jing","year":"2016","unstructured":"Jing YJ, Ni JW, Ding FH, et al. P-cresyl sulfate is associated with carotid arteriosclerosis in hemodialysis patients and promotes atherogenesis in apoE-\/- mice. Kidney Int. 2016;89(2):439\u201349.","journal-title":"Kidney Int"},{"issue":"5","key":"1587_CR27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.ajkd.2009.04.022","volume":"54","author":"BK Meijers","year":"2009","unstructured":"Meijers BK, Kerckhoven SV, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis. 2009;54(5):891\u2013901.","journal-title":"Am J Kidney Dis"},{"key":"1587_CR28","doi-asserted-by":"crossref","unstructured":"Opdebeeck B, D'Haese PC, Verhulst A. Molecular and cellular mechanisms that induce arterial calcification by indoxyl sulfate and P-cresyl sulfate. Toxins (Basel). 2020;12(1):58","DOI":"10.3390\/toxins12010058"},{"key":"1587_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010531","author":"E Harlacher","year":"2022","unstructured":"Harlacher E, Wollenhaupt J, Baaten CC, et al. Impact of uremic toxins on endothelial dysfunction in chronic kidney disease: a systematic review. Int J Mol Sci. 2022;23(1):531.\u00a0https:\/\/doi.org\/10.3390\/ijms23010531.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1587_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/ndt\/gfab004","volume":"36","author":"G Glorieux","year":"2021","unstructured":"Glorieux G, Vanholder R, Biesen WV, et al. Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol Dial Transplant. 2021;36(6):998\u20131005.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1587_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132589","volume":"10","author":"CJ Lin","year":"2015","unstructured":"Lin CJ, Wu V, Wu PC, et al. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS ONE. 2015;10(7):e0132589.","journal-title":"PLoS ONE"},{"key":"1587_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2369-15-87","volume":"15","author":"R Poesen","year":"2014","unstructured":"Poesen R, Viaene L, Verbeke K, et al. Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrol. 2014;15:87.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1587_CR33","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1038\/s41598-021-83383-x","volume":"11","author":"PH Wu","year":"2021","unstructured":"Wu PH, Lin YT, Chiu YW, et al. The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients. Sci Rep. 2021;11(1):3786.","journal-title":"Sci Rep"},{"key":"1587_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186687","author":"CY Sun","year":"2020","unstructured":"Sun CY, Li JR, Wang YY, et al. P-cresol sulfate caused behavior disorders and neurodegeneration in mice with unilateral nephrectomy involving oxidative stress and neuroinflammation. Int J Mol Sci. 2020;21(18):6687. https:\/\/doi.org\/10.3390\/ijms21186687.","journal-title":"Int J Mol Sci"},{"key":"1587_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10050202","author":"H Fujii","year":"2018","unstructured":"Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins (Basel). 2018;10(5):202. https:\/\/doi.org\/10.3390\/toxins10050202.","journal-title":"Toxins (Basel)"},{"issue":"2","key":"1587_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bone.2013.07.002","volume":"56","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Iwasaki Y, Yamato H, et al. P-cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone. 2013;56(2):347\u201354.","journal-title":"Bone"},{"issue":"1","key":"1587_CR37","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1038\/s41598-019-39646-9","volume":"9","author":"TK Wu","year":"2019","unstructured":"Wu TK, Wei CW, Pan YR, et al. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell renal cell carcinoma via microRNA-21\/ HIF-1\u03b1 axis signals. Sci Rep. 2019;9(1):3207.","journal-title":"Sci Rep"},{"issue":"4","key":"1587_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10565-019-09509-0","volume":"36","author":"YS Peng","year":"2020","unstructured":"Peng YS, Syu JP, Wang SD, et al. BSA-bounded p-cresyl sulfate potentiates the malignancy of bladder carcinoma by triggering cell migration and EMT through the ROS\/Src\/FAK signaling pathway. Cell Biol Toxicol. 2020;36(4):287\u2013300.","journal-title":"Cell Biol Toxicol"},{"key":"1587_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061257","author":"R Di Paola","year":"2023","unstructured":"Di Paola R, De A, Izhar R, et al. Possible effects of uremic toxins p-cresol, indoxyl sulfate, p-cresyl sulfate on the development and progression of colon cancer in patients with chronic renal failure. Genes. 2023;14(6):1257. https:\/\/doi.org\/10.3390\/genes14061257.","journal-title":"Genes"},{"key":"1587_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030434","author":"DD Weber","year":"2021","unstructured":"Weber DD, Thapa M, Aminzadeh-Gohari S, et al. Targeted metabolomics identifies plasma biomarkers in mice with metabolically heterogeneous melanoma xenografts. Cancers (Basel). 2021;13(3):434. https:\/\/doi.org\/10.3390\/cancers13030434.","journal-title":"Cancers (Basel)"},{"key":"1587_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10010033","author":"R Vanholder","year":"2018","unstructured":"Vanholder R, Pletinck A, Schepers E, et al. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018;10(1):33. https:\/\/doi.org\/10.3390\/toxins10010033.","journal-title":"Toxins (Basel)"},{"key":"1587_CR42","volume":"2014","author":"CJ Lin","year":"2014","unstructured":"Lin CJ, Pan CF, Chuang CK, et al. P-cresyl sulfate is a valuable predictor of clinical outcomes in pre-ESRD patients. BioMed Res Int. 2014;2014:526932.","journal-title":"BioMed Res Int"},{"issue":"4","key":"1587_CR43","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/ndt\/gfp592","volume":"25","author":"S Liabeuf","year":"2010","unstructured":"Liabeuf S, Barreto D, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010;25(4):1183\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087452","author":"V Dehghan Niestanak","year":"2023","unstructured":"Dehghan Niestanak V, Unsworth LD. Detailing protein-bound uremic toxin interaction mechanisms with human serum albumin in the pursuit of designing competitive binders. Int J Mol Sci. 2023;24(8):7452.\u00a0https:\/\/doi.org\/10.3390\/ijms24087452.","journal-title":"Int J Mol Sci"},{"key":"1587_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113551","volume":"191","author":"YR Ma","year":"2020","unstructured":"Ma YR, Xin MY, Li K, et al. An LC-MS\/MS analytical method for the determination of uremic toxins in patients with end-stage renal disease. J Pharm Biomed Anal. 2020;191:113551.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1587_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11306-023-01978-z","volume":"19","author":"N Ragi","year":"2023","unstructured":"Ragi N, Pallerla P, Gari AR, et al. Assessment of uremic toxins in advanced chronic kidney disease patients on maintenance hemodialysis by LC-ESI-MS\/MS. Metabolomics. 2023;19(3):14.","journal-title":"Metabolomics"},{"issue":"7","key":"1587_CR47","doi-asserted-by":"publisher","first-page":"300060520933797","DOI":"10.1177\/0300060520933797","volume":"48","author":"BC Cheng","year":"2020","unstructured":"Cheng BC, Lai YR, Huang CC, et al. Improved cardiovascular autonomic function and decreased protein-bound uremic toxins in patients with end-stage renal disease after peritoneal dialysis. J Int Med Res. 2020;48(7):300060520933797.","journal-title":"J Int Med Res"},{"issue":"12","key":"1587_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.34067\/KID.0000272020","volume":"1","author":"E Te Linde","year":"2020","unstructured":"Te Linde E, Van Roij C, Meijers BK, et al. Cognitive function and uremic toxins after kidney transplantation: an exploratory study. Kidney360. 2020;1(12):1398\u2013406.","journal-title":"Kidney360"},{"issue":"10","key":"1587_CR49","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/ndt\/gfw009","volume":"31","author":"R Poesen","year":"2016","unstructured":"Poesen R, Evenepoel P, De Loor H, et al. The influence of renal transplantation on retained microbial-human co-metabolites. Nephrol Dial Transplant. 2016;31(10):1721\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10060229","author":"S Liabeuf","year":"2018","unstructured":"Liabeuf S, Cheddani L, Massy ZA. Uremic toxins and clinical outcomes: the impact of kidney transplantation. Toxins (Basel). 2018;10(6):229.\u00a0https:\/\/doi.org\/10.3390\/toxins10060229.","journal-title":"Toxins (Basel)"},{"issue":"1","key":"1587_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/17512433.2018.1378095","volume":"11","author":"AJ Prokopienko","year":"2018","unstructured":"Prokopienko AJ, Nolin TD. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert Rev Clin Pharmacol. 2018;11(1):71\u201382.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1587_CR52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/advances\/nmab149","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Shi J, Ma X, et al. Effects of microbiota-driven therapy on circulating indoxyl sulfate and p-cresyl sulfate in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2022;13(4):1267\u201378.","journal-title":"Adv Nutr"},{"issue":"3","key":"1587_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.7150\/ijms.51484","volume":"18","author":"L Jia","year":"2021","unstructured":"Jia L, Dong X, Li X, et al. Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis. Int J Med Sci. 2021;18(3):811\u201320.","journal-title":"Int J Med Sci"},{"issue":"5","key":"1587_CR54","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1159\/000494677","volume":"43","author":"L Jia","year":"2018","unstructured":"Jia L, Jia Q, Yang J, et al. Efficacy of probiotics supplementation on chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(5):1623\u201335.","journal-title":"Kidney Blood Press Res"},{"key":"1587_CR55","doi-asserted-by":"publisher","first-page":"1434613","DOI":"10.3389\/fnut.2024.1434613","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu C, Yang L, Wei W, et al. Efficacy of probiotics\/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2024;11:1434613.","journal-title":"Front Nutr"},{"issue":"1","key":"1587_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.jrn.2021.08.005","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu J, Zhong J, Yang H, et al. Biotic supplements in patients with chronic kidney disease: meta-analysis of randomized controlled trials. J Ren Nutr. 2022;32(1):10\u201321.","journal-title":"J Ren Nutr"},{"issue":"3","key":"1587_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.jrn.2018.08.008","volume":"29","author":"C McFarlane","year":"2019","unstructured":"McFarlane C, Ramos CI, Johnson DW, et al. Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr. 2019;29(3):209\u201320.","journal-title":"J Ren Nutr"},{"key":"1587_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194456","author":"TTU Nguyen","year":"2021","unstructured":"Nguyen TTU, Kim HW, Kim W. Effects of probiotics, prebiotics, and synbiotics on uremic toxins, inflammation, and oxidative stress in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(19):4456\u00a0https:\/\/doi.org\/10.3390\/jcm10194456.","journal-title":"J Clin Med"},{"key":"1587_CR59","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/673631","volume":"2012","author":"M Rossi","year":"2012","unstructured":"Rossi M, Klein K, Johnson DW, et al. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol. 2012;2012:673631.","journal-title":"Int J Nephrol"},{"issue":"6","key":"1587_CR60","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40620-020-00955-2","volume":"34","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn K, Wuttiputinun T, Phannajit J, et al. Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis. J Nephrol. 2021;34(6):1805\u201317.","journal-title":"J Nephrol"},{"issue":"2","key":"1587_CR61","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10620-018-5243-9","volume":"64","author":"C Thongprayoon","year":"2019","unstructured":"Thongprayoon C, Kaewput W, Hatch ST, et al. Effects of probiotics on inflammation and uremic toxins among patients on dialysis: a systematic review and meta-analysis. Dig Dis Sci. 2019;64(2):469\u201379.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"1587_CR62","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1053\/j.jrn.2020.11.008","volume":"31","author":"HL Yang","year":"2021","unstructured":"Yang HL, Feng P, Xu Y, et al. The role of dietary fiber supplementation in regulating uremic toxins in patients with chronic kidney disease: a meta-analysis of randomized controlled trials. J Ren Nutr. 2021;31(5):438\u201347.","journal-title":"J Ren Nutr"},{"key":"1587_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.850425","volume":"9","author":"Z Yu","year":"2022","unstructured":"Yu Z, Zhao J, Qin Y, et al. Probiotics, prebiotics, and synbiotics improve uremic, inflammatory, and gastrointestinal symptoms in end-stage renal disease with dialysis: a network meta-analysis of randomized controlled trials. Front Nutr. 2022;9:850425.","journal-title":"Front Nutr"},{"issue":"2","key":"1587_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2416609","volume":"46","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Hu XY, Yang SY, et al. Effects of resistant starch supplementation on renal function and inflammatory markers in patients with chronic kidney disease: a meta-analysis of randomized controlled trials. Ren Fail. 2024;46(2):2416609.","journal-title":"Ren Fail"},{"key":"1587_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/nu17071247","author":"R Cedillo-Flores","year":"2025","unstructured":"Cedillo-Flores R, Cuevas-Budhart MA, Cavero-Redondo I, et al. Impact of gut microbiome modulation on uremic toxin reduction in chronic kidney disease: a systematic review and network meta-analysis. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17071247.","journal-title":"Nutrients"},{"issue":"4","key":"1587_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1053\/j.jrn.2019.07.006","volume":"30","author":"DS March","year":"2020","unstructured":"March DS, Jones AW, Bishop NC, et al. The efficacy of prebiotic, probiotic, and synbiotic supplementation in modulating gut-derived circulatory particles associated with cardiovascular disease in individuals receiving dialysis: a systematic review and meta-analysis of randomized controlled trials. J Ren Nutr. 2020;30(4):347\u201359.","journal-title":"J Ren Nutr"},{"issue":"2","key":"1587_CR67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5935\/0101-2800.20140033","volume":"36","author":"FC Barreto","year":"2014","unstructured":"Barreto FC, Marques Stinghen AE, de Oliveira RB, et al. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol. 2014;36(2):221\u201335.","journal-title":"J Bras Nefrol"},{"issue":"12","key":"1587_CR68","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/ckj\/sfac154","volume":"15","author":"BM Beker","year":"2022","unstructured":"Beker BM, Colombo I, Gonzalez-Torres H, et al. Decreasing microbiota-derived uremic toxins to improve CKD outcomes. Clin Kidney J. 2022;15(12):2214\u20139.","journal-title":"Clin Kidney J"},{"issue":"5","key":"1587_CR69","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/advances\/nmz028","volume":"10","author":"S Chung","year":"2019","unstructured":"Chung S, Barnes JL, Astroth KS. Gastrointestinal microbiota in patients with chronic kidney disease: a systematic review. Adv Nutr. 2019;10(5):888\u2013901.","journal-title":"Adv Nutr"},{"issue":"10","key":"1587_CR70","first-page":"CD013631","volume":"10","author":"TE Cooper","year":"2023","unstructured":"Cooper TE, Khalid R, Chan S, et al. Synbiotics, prebiotics and probiotics for people with chronic kidney disease. Cochrane Database Syst Rev. 2023;10(10):CD013631.","journal-title":"Cochrane Database Syst Rev"},{"key":"1587_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163503","author":"V Faerber","year":"2023","unstructured":"Faerber V, Kuhn KS, Garneata L, et al. The microbiome and protein carbamylation: potential targets for protein-restricted diets supplemented with ketoanalogues in predialysis chronic kidney disease. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15163503.","journal-title":"Nutrients"},{"key":"1587_CR72","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221100023","volume":"9","author":"K Kingra","year":"2022","unstructured":"Kingra K, Curtis S, Mollard RC, et al. The effects of resistant starch consumption in adult patients with chronic kidney disease: a systematic review. Can J Kidney Health Dis. 2022;9:20543581221100023.","journal-title":"Can J Kidney Health Dis"},{"issue":"5","key":"1587_CR73","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ki.2015.255","volume":"88","author":"L Koppe","year":"2015","unstructured":"Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015;88(5):958\u201366.","journal-title":"Kidney Int"},{"issue":"4","key":"1587_CR74","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.kint.2022.06.025","volume":"102","author":"L Koppe","year":"2022","unstructured":"Koppe L, Soulage CO. The impact of dietary nutrient intake on gut microbiota in the progression and complications of chronic kidney disease. Kidney Int. 2022;102(4):728\u201339.","journal-title":"Kidney Int"},{"key":"1587_CR75","doi-asserted-by":"crossref","unstructured":"Laville SM, Massy ZA, Kamel S, et al. Intestinal chelators, sorbants, and gut-derived uremic toxins. Toxins (Basel). 2021;13(2).","DOI":"10.3390\/toxins13020091"},{"issue":"10","key":"1587_CR76","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1253\/circj.CJ-15-0749","volume":"79","author":"S Lekawanvijit","year":"2015","unstructured":"Lekawanvijit S. Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities. Circ J. 2015;79(10):2088\u201397.","journal-title":"Circ J"},{"key":"1587_CR77","doi-asserted-by":"crossref","unstructured":"Lu PH, Yu MC, Wei MJ, et al. The therapeutic strategies for uremic toxins control in chronic jidney disease. Toxins (Basel). 2021;13(8).","DOI":"10.3390\/toxins13080573"},{"key":"1587_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15090548","author":"L Mitrea","year":"2023","unstructured":"Mitrea L, Medeleanu M, Pop CR, et al. Biotics (pre-, pro-, post-) and uremic toxicity: implications, mechanisms, and possible therapies. Toxins (Basel). 2023;15,548.\u00a0https:\/\/doi.org\/10.3390\/toxins15090548.","journal-title":"Toxins (Basel)"},{"key":"1587_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910429","author":"E M\u0142ynarska","year":"2024","unstructured":"M\u0142ynarska E, Budny E, Saar M, et al. Does the composition of gut microbiota affect chronic kidney disease? Molecular mechanisms contributed to decreasing glomerular filtration rate. Int J Mol Sci. 2024;25,10429. https:\/\/doi.org\/10.3390\/ijms251910429.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1587_CR80","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00394-015-1138-0","volume":"55","author":"C Moraes","year":"2016","unstructured":"Moraes C, Borges NA, Mafra D. Resistant starch for modulation of gut microbiota: promising adjuvant therapy for chronic kidney disease patients? Eur J Nutr. 2016;55(5):1813\u201321.","journal-title":"Eur J Nutr"},{"issue":"2","key":"1587_CR81","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11255-017-1689-5","volume":"50","author":"W Pan","year":"2018","unstructured":"Pan W, Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol. 2018;50(2):289\u201399.","journal-title":"Int Urol Nephrol"},{"key":"1587_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172892","volume":"868","author":"Y Rahbar Saadat","year":"2020","unstructured":"Rahbar Saadat Y, Niknafs B, Hosseiniyan Khatibi SM, et al. Gut microbiota; an overlooked effect of phosphate binders. Eur J Pharmacol. 2020;868:172892.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1587_CR83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1053\/j.ajkd.2015.09.027","volume":"67","author":"A Ramezani","year":"2016","unstructured":"Ramezani A, Massy ZA, Meijers B, et al. Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis. 2016;67(3):483\u201398.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1587_CR84","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14728222.2020.1762173","volume":"24","author":"S Rayego-Mateos","year":"2020","unstructured":"Rayego-Mateos S, Valdivielso JM. New therapeutic targets in chronic kidney disease progression and renal fibrosis. Expert Opin Ther Targets. 2020;24(7):655\u201370.","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"1587_CR85","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/joim.13248","volume":"290","author":"V Saar-Kovrov","year":"2021","unstructured":"Saar-Kovrov V, Zidek W, Orth-Alampour S, et al. Reduction of protein-bound uraemic toxins in plasma of chronic renal failure patients: a systematic review. J Intern Med. 2021;290(3):499\u2013526.","journal-title":"J Intern Med"},{"key":"1587_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194044","author":"N Tian","year":"2022","unstructured":"Tian N, Li L, Ng JK, et al. The potential benefits and controversies of probiotics use in patients at different stages of chronic kidney disease. Nutrients. 2022;14(19):4044. https:\/\/doi.org\/10.3390\/nu14194044.","journal-title":"Nutrients"},{"issue":"4","key":"1587_CR87","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1053\/j.ajkd.2015.08.029","volume":"67","author":"RC Vanholder","year":"2016","unstructured":"Vanholder RC, Eloot S, Glorieux GL. Future avenues to decrease uremic toxin concentration. Am J Kidney Dis. 2016;67(4):664\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1587_CR88","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/toxins5112042","volume":"5","author":"L Vitetta","year":"2013","unstructured":"Vitetta L, Linnane AW, Gobe GC. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins (Basel). 2013;5(11):2042\u201357.","journal-title":"Toxins (Basel)"},{"key":"1587_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7080228","author":"L Vitetta","year":"2019","unstructured":"Vitetta L, Llewellyn H, Oldfield D. Gut dysbiosis and the intestinal microbiome: Streptococcus thermophilus a key probiotic for reducing uremia. Microorganisms. 2019;7(8):228. https:\/\/doi.org\/10.3390\/microorganisms7080228.","journal-title":"Microorganisms"},{"key":"1587_CR90","doi-asserted-by":"publisher","first-page":"1123182","DOI":"10.3389\/fphys.2023.1123182","volume":"14","author":"Y Xu","year":"2023","unstructured":"Xu Y, Bi WD, Shi YX, et al. Derivation and elimination of uremic toxins from kidney-gut axis. Front Physiol. 2023;14:1123182.","journal-title":"Front Physiol"},{"key":"1587_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14040245","author":"N Zaidan","year":"2022","unstructured":"Zaidan N, Nazzal L. The microbiome and uremic solutes. Toxins (Basel). 2022;14(4):245.\u00a0https:\/\/doi.org\/10.3390\/toxins14040245.","journal-title":"Toxins (Basel)"},{"key":"1587_CR92","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171694","author":"X Chen","year":"2018","unstructured":"Chen, X., Gao, S., & Ruan, M. et al. Shen-shuai-ning granule decreased serum concentrations of indoxyl sulphate in uremic patients undergoing peritoneal dialysis, Biosci Rep, https:\/\/doi.org\/10.1042\/BSR20171694 (2018)."},{"key":"1587_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16100416","author":"L Fonseca","year":"2024","unstructured":"Fonseca L, Ribeiro M, Schultz J, et al. Effects of propolis supplementation on gut microbiota and uremic toxin profiles of patients undergoing hemodialysis. Toxins (Basel). 2024;16,416. https:\/\/doi.org\/10.3390\/toxins16100416.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"1587_CR94","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2215\/CJN.05240418","volume":"14","author":"M Madero","year":"2019","unstructured":"Madero M, Cano KB, Campos I, et al. Removal of protein-bound uremic toxins during hemodialysis using a binding competitor. Clin J Am Soc Nephrol. 2019;14(3):394\u2013402.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1587_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100315","author":"S Marzocco","year":"2018","unstructured":"Marzocco S, Fazeli G, Di Micco L, et al. Supplementation of short-chain fatty acid, sodium propionate, in patients on maintenance hemodialysis: beneficial effects on inflammatory parameters and gut-derived uremic toxins, a pilot study (PLAN Study). J Clin Med. 2018;7,315. https:\/\/doi.org\/10.3390\/jcm7100315.","journal-title":"J Clin Med"},{"key":"1587_CR96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clnesp.2021.11.012","volume":"47","author":"KTR Teixeira","year":"2022","unstructured":"Teixeira KTR, Moreira LDSG, Borges NA, et al. Effect of cranberry supplementation on toxins produced by the gut microbiota in chronic kidney disease patients: a pilot randomized placebo-controlled trial. Clin Nutr ESPEN. 2022;47:63\u20139.","journal-title":"Clin Nutr ESPEN"},{"issue":"6","key":"1587_CR97","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1053\/j.jrn.2022.01.010","volume":"32","author":"L Alvarenga","year":"2022","unstructured":"Alvarenga L, Cardozo LFMF, de O Leal V, et al. Can resveratrol supplementation reduce uremic toxin plasma levels from the gut microbiota in nondialyzed patients with chronic kidney disease? J Ren Nutr. 2022;32(6):685\u201391.","journal-title":"J Ren Nutr"},{"key":"1587_CR98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJNRD.S41339","volume":"7","author":"G Schulman","year":"2014","unstructured":"Schulman G, Vanholder R, Niwa T. AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:49\u201356.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"1587_CR99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/0886022X.2018.1561376","volume":"41","author":"M Asai","year":"2019","unstructured":"Asai M, Kumakura S, Kikuchi M. Review of the efficacy of AST-120 (Kremezin\u00ae) on renal function in chronic kidney disease patients. Ren Fail. 2019;41(1):47\u201356.","journal-title":"Ren Fail"},{"key":"1587_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092234","author":"CK Hsu","year":"2022","unstructured":"Hsu CK, Su SC, Chang LC, et al. Oral absorbent AST-120 is associated with compositional and functional adaptations of gut microbiota and modification of serum short and medium-chain fatty acids in advanced CKD patients. Biomedicines. 2022;10,2234. https:\/\/doi.org\/10.3390\/biomedicines10092234.","journal-title":"Biomedicines"},{"key":"1587_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10090367","author":"WC Liu","year":"2018","unstructured":"Liu WC, Tomino Y, Lu KC. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120. Toxins (Basel). 2018;10(9):367.\u00a0https:\/\/doi.org\/10.3390\/toxins10090367.","journal-title":"Toxins (Basel)"},{"key":"1587_CR102","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.1038\/srep14381","volume":"5","author":"S Yamamoto","year":"2015","unstructured":"Yamamoto S, Kazama JJ, Omori K, et al. Continuous reduction of protein-bound uraemic toxins with improved oxidative stress by using the oral charcoal adsorbent AST-120 in haemodialysis patients. Sci Rep. 2015;5:14381.","journal-title":"Sci Rep"},{"issue":"5","key":"1587_CR103","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/ndt\/10.5.671","volume":"10","author":"K Okada","year":"1995","unstructured":"Okada K, Takahashi S. Correction by oral adsorbent of abnormal digestive tract milieu in rats with chronic renal failure. Nephrol Dial Transplant. 1995;10(5):71\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1587_CR104","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/ndt\/gfp007","volume":"24","author":"H Fujii","year":"2009","unstructured":"Fujii H, Nishijima F, Goto S, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24(7):2089\u201395.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1587_CR105","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/ndt\/gfl311","volume":"21","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Yamato H, Nii-Kono T, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant. 2006;21(10):2768\u201374.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1587_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.23736\/S0031-0808.16.03272-9","volume":"59","author":"T Niwa","year":"2017","unstructured":"Niwa T. The role of carbon adsorbent in the conservative management of chronic kidney disease. Panminerva Med. 2017;59(2):139\u201348.","journal-title":"Panminerva Med"},{"issue":"9","key":"1587_CR107","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ndt\/gfu061","volume":"29","author":"IW Wu","year":"2014","unstructured":"Wu IW, Hsu KH, Sun CY, et al. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on stage 5 chronic kidney disease patients: a randomized crossover study. Nephrol Dial Transplant. 2014;29(9):1719\u201327.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1587_CR108","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000357641","volume":"37","author":"CT Lee","year":"2014","unstructured":"Lee CT, Hsu CY, Tain YL, et al. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purif. 2014;37(1):76\u201383.","journal-title":"Blood Purif"},{"issue":"3","key":"1587_CR109","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.jrn.2006.04.006","volume":"16","author":"A Duggal","year":"2006","unstructured":"Duggal A, Hanus M, Zhorov E, et al. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr. 2006;16(3):248\u201352.","journal-title":"J Ren Nutr"},{"issue":"1","key":"1587_CR110","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-200868010-00006","volume":"68","author":"DR Goldsmith","year":"2008","unstructured":"Goldsmith DR, Scott LJ, Cvetkovi\u00b4c RS, et al. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs. 2008;68(1):85\u2013104.","journal-title":"Drugs"},{"issue":"6","key":"1587_CR111","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/ndt\/gfh125","volume":"19","author":"GM Chertow","year":"2004","unstructured":"Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1489\u201396.","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR112","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/IJNRD.S41626","volume":"7","author":"S Ossareh","year":"2014","unstructured":"Ossareh S. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. Int J Nephrol Renovasc Dis. 2014;7:161\u20138.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"1587_CR113","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1345\/aph.1M291","volume":"44","author":"MM Barna","year":"2010","unstructured":"Barna MM, Kapoian T, O\u2019Mara NB. Sevelamer carbonate. Ann Pharmacother. 2010;44(1):127\u201334.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1587_CR114","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2169\/internalmedicine.48.1817","volume":"48","author":"I Ohno","year":"2009","unstructured":"Ohno I, Yamaguchi Y, Saikawa H,\u00a0et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med. 2009;48(6):415\u201320.","journal-title":"Intern Med"},{"issue":"7","key":"1587_CR115","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/dom.13272","volume":"20","author":"A Br\u00f8nden","year":"2018","unstructured":"Br\u00f8nden A, Mikkelsen K, Sonne DP, et al. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. Diabetes Obes Metab. 2018;20(7):1623\u201331.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1587_CR116","first-page":"381","volume":"50","author":"BM Wilkes","year":"1998","unstructured":"Wilkes BM, Reiner D, Kern M, et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol. 1998;50(6):381\u20136.","journal-title":"Clin Nephrol"},{"issue":"5","key":"1587_CR117","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1046\/j.1523-1755.2003.00284.x","volume":"64","author":"M Cozzolino","year":"2003","unstructured":"Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 2003;64(5):1653\u201361.","journal-title":"Kidney Int"},{"issue":"9","key":"1587_CR118","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ki.2009.60","volume":"75","author":"AJ Hutchison","year":"2009","unstructured":"Hutchison AJ. Oral phosphate binders. Kidney Int. 2009;75(9):906\u201314.","journal-title":"Kidney Int"},{"issue":"10","key":"1587_CR119","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/ndt\/gfh446","volume":"19","author":"AK Pieper","year":"2004","unstructured":"Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19(10):2630\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1587_CR120","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","volume":"22","author":"E Riccio","year":"2018","unstructured":"Riccio E, Sabbatini M, Bruzzese D, et al. Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol. 2018;22(3):529\u201338.","journal-title":"Clin Exp Nephrol"},{"key":"1587_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13100688","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn K, Puapatanakul P, Phannajit J, et al. Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia: a randomized controlled trial. Toxins (Basel). 2021;13:688. https:\/\/doi.org\/10.3390\/toxins13100688.","journal-title":"Toxins (Basel)"},{"issue":"9","key":"1587_CR122","doi-asserted-by":"publisher","first-page":"765","DOI":"10.14740\/jocmr1803e","volume":"9","author":"CJ Lin","year":"2017","unstructured":"Lin CJ, Pan CF, Chuang CK, et al. Effects of sevelamer hydrochloride on uremic toxins serum indoxyl sulfate and p-cresyl sulfate in hemodialysis patients. J Clin Med Res. 2017;9(9):765\u201370.","journal-title":"J Clin Med Res"},{"issue":"8","key":"1587_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073558","volume":"8","author":"B Guida","year":"2013","unstructured":"Guida B, Cataldi M, Riccio E, et al. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a cross-sectional observational study. PLoS ONE. 2013;8(8):e73558.","journal-title":"PLoS ONE"},{"key":"1587_CR124","doi-asserted-by":"crossref","unstructured":"Bennis Y, Cluet Y, Titeca-Beauport D, et al. The effect of sevelamer on serum levels of gut-derived uremic toxins: results from in vitro experiments and a multicenter, double-blind, placebo-controlled, randomized clinical trial. Toxins (Basel), 2019;11(5).","DOI":"10.3390\/toxins11050279"},{"issue":"12","key":"1587_CR125","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.2215\/CJN.03030317","volume":"12","author":"S Liabeuf","year":"2017","unstructured":"Liabeuf S, Ryckelynck JP, Esper NE, et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clin J Am Soc Nephrol. 2017;12(12):1930\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1587_CR126","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfw042","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet A, Liabeuf S, Esper NEL\u00a0et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017;32(5):870\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1587_CR127","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-019-01118-9","volume":"79","author":"A Lenglet","year":"2019","unstructured":"Lenglet A, Fabresse N, Taupin M,\u00a0et al. Does the administration of sevelamer or nicotinamide modify uremic toxins or endotoxemia in chronic hemodialysis patients? Drugs. 2019;79(8):855\u201362.","journal-title":"Drugs"},{"issue":"8","key":"1587_CR128","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1159\/000517470","volume":"51","author":"LC Wang","year":"2022","unstructured":"Wang LC, Tapia LM, Tao X, et al. Gut microbiome-derived uremic toxin levels in hemodialysis patients on different phosphate binder therapies. Blood Purif. 2022;51(8):639\u201348.","journal-title":"Blood Purif"},{"key":"1587_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12060351","author":"L Dai","year":"2020","unstructured":"Dai L, Meijers BK, Bammens B, et al. Sevelamer use in end-stage kidney disease (ESKD) patients associates with poor vitamin K status and high levels of gut-derived uremic toxins: a drug-bug interaction? Toxins (Basel). 2020;12:351. https:\/\/doi.org\/10.3390\/toxins12060351.","journal-title":"Toxins (Basel)"},{"issue":"8","key":"1587_CR130","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/ndt\/gfq053","volume":"25","author":"VM Brandenburg","year":"2010","unstructured":"Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant. 2010;25(8):2672\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1587_CR131","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s40620-022-01271-7","volume":"35","author":"T Arcidiacono","year":"2022","unstructured":"Arcidiacono T, Macrina L, Premaschi S, et al. Serum concentrations of free indoxyl and p-cresyl sulfate are associated with mineral metabolism variables and cardiovascular risk in hemodialysis patients. J Nephrol. 2022;35(5):1457\u201365.","journal-title":"J Nephrol"},{"issue":"1","key":"1587_CR132","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/ehf2.14566","volume":"11","author":"B Zwaenepoel","year":"2024","unstructured":"Zwaenepoel B, De Backer T, Glorieux G, et al. Predictive value of protein-bound uremic toxins for heart failure in patients with chronic kidney disease. ESC Heart Fail. 2024;11(1):466\u201374.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"1587_CR133","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1592\/phco.29.5.554","volume":"29","author":"AB Pai","year":"2009","unstructured":"Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009;29(5):554\u201361.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1587_CR134","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-014-0215-7","volume":"74","author":"CM Perry","year":"2014","unstructured":"Perry CM, Plosker GL. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease. Drugs. 2014;74(7):771\u201392.","journal-title":"Drugs"},{"issue":"11","key":"1587_CR135","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/ndt\/gfab114","volume":"37","author":"C Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 C, Choukroun G, Bennis Y, et al. Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors. Nephrol Dial Transplant. 2022;37(11):2284\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1587_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14010015","volume":"14","author":"C Andre","year":"2021","unstructured":"Andre C, Mernissi T, Choukroun G, et al. The prescription of drugs that inhibit organic anion transporters 1 or 3 is associated with the plasma accumulation of uremic toxins in kidney transplant recipients. Toxins (Basel). 2021;14(1):15.","journal-title":"Toxins (Basel)"},{"issue":"7","key":"1587_CR137","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/07315724.2017.1334602","volume":"36","author":"B Guida","year":"2017","unstructured":"Guida B, Cataldi M, Memoli A, et al. Effect of a short-course treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients. J Am Coll Nutr. 2017;36(7):586\u201391.","journal-title":"J Am Coll Nutr"},{"issue":"7","key":"1587_CR138","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.transproceed.2015.02.033","volume":"47","author":"G Ligabue","year":"2015","unstructured":"Ligabue G, Damiano F, Cuoghi A,\u00a0et al. P-cresol and cardiovascular risk in kidney transplant recipients. Transplant Proc. 2015;47(7):2121\u20135.","journal-title":"Transplant Proc"},{"issue":"3","key":"1587_CR139","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40261-022-01121-1","volume":"42","author":"Y Rong","year":"2022","unstructured":"Rong Y, Colbourne P, Gourishankar S, et al. Significant correlations between p-cresol sulfate and mycophenolic acid plasma concentrations in adult kidney transplant recipients. Clin Drug Invest. 2022;42(3):207\u201319.","journal-title":"Clin Drug Invest"},{"issue":"10","key":"1587_CR140","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2174\/1389200216666150206124424","volume":"15","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Funk F, Rakov V, et al. Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab. 2014;15(10):953\u201365.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"1587_CR141","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40620-021-01241-5","volume":"35","author":"DW Coyne","year":"2022","unstructured":"Coyne DW, Sprague SM, Vervloet M, et al. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022;35(3):875\u201388.","journal-title":"J Nephrol"},{"issue":"15","key":"1587_CR142","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1080\/14656566.2023.2243817","volume":"24","author":"V Cernaro","year":"2023","unstructured":"Cernaro V, Longhitano E, Calabrese V, et al. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Expert Opin Pharmacother. 2023;24(15):1737\u201346.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"1587_CR143","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10157-020-01892-x","volume":"24","author":"A Iguchi","year":"2020","unstructured":"Iguchi A, Yamamoto S, Oda A, et al. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis. Clin Exp Nephrol. 2020;24(8):725\u201333.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1587_CR144","first-page":"330","volume":"24","author":"HH Shah","year":"2015","unstructured":"Shah HH, Hazzan AD, Fishbane S. Novel iron-based phosphate binders in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24(4):330\u20135.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"1587_CR145","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/ndt\/gfaa080","volume":"35","author":"E Neven","year":"2020","unstructured":"Neven E, Corremans R, Vervaet BA, et al. Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure. Nephrol Dial Transplant. 2020;35(10):1689\u201399.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1587_CR146","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41598-018-38389-3","volume":"9","author":"Y Nemoto","year":"2019","unstructured":"Nemoto Y, Kumagai T, Ishizawa K, et al. Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model. Sci Rep. 2019;9(1):1732.","journal-title":"Sci Rep"},{"issue":"5","key":"1587_CR147","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nefroe.2021.04.012","volume":"42","author":"MA Bajo","year":"2022","unstructured":"Bajo MA, Rios-Moreno F, Arenas MD, et al. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study. Nefrologia (Engl Ed). 2022;42(5):594\u2013606.","journal-title":"Nefrologia (Engl Ed)"},{"issue":"1","key":"1587_CR148","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000531869","volume":"148","author":"J Liu","year":"2024","unstructured":"Liu J, Zuo L, Walpen S, et al. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: a randomised, open-label, multicentre, 12-week phase III study. Nephron. 2024;148(1):22\u201333.","journal-title":"Nephron"},{"issue":"3","key":"1587_CR149","doi-asserted-by":"publisher","first-page":"251","DOI":"10.21101\/cejph.a5313","volume":"27","author":"E Hijov\u00e1","year":"2019","unstructured":"Hijov\u00e1 E, Bertkov\u00e1 I, \u0160tofilov\u00e1 J. Dietary fibre as prebiotics in nutrition. Cent Eur J Public Health. 2019;27(3):251\u20135.","journal-title":"Cent Eur J Public Health"},{"issue":"4","key":"1587_CR150","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/nu5041417","volume":"5","author":"J Slavin","year":"2013","unstructured":"Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5(4):1417\u201335.","journal-title":"Nutrients"},{"issue":"4","key":"1587_CR151","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1021\/jf802484j","volume":"57","author":"DC Hernot","year":"2009","unstructured":"Hernot DC, Boileau TW, Bauer LL, et al. In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem. 2009;57(4):354\u201361.","journal-title":"J Agric Food Chem"},{"issue":"3","key":"1587_CR152","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2672.1996.tb04331.x","volume":"81","author":"EA Smith","year":"1996","unstructured":"Smith EA, Macfarlane GT. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol. 1996;81(3):288\u2013302.","journal-title":"J Appl Bacteriol"},{"key":"1587_CR153","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/ki.2009.402","volume":"114","author":"P Evenepoe","year":"2009","unstructured":"Evenepoe P, Meijers BK, Bammens BRM, et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl. 2009;114:S12\u20139.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"1587_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268624","volume":"17","author":"JA Hall","year":"2022","unstructured":"Hall JA, Jewell DE, Ephraim E. Feeding cats with chronic kidney disease food supplemented with betaine and prebiotics increases total body mass and reduces uremic toxins. PLoS ONE. 2022;17(5):e0268624.","journal-title":"PLoS ONE"},{"issue":"10","key":"1587_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258145","volume":"16","author":"E Melekoglu","year":"2021","unstructured":"Melekoglu E, Cetinkaya MA, Kepekci-Tekkeli SE, et al. Effects of prebiotic oligofructose-enriched inulin on gut-derived uremic toxins and disease progression in rats with adenine-induced chronic kidney disease. PLoS ONE. 2021;16(10):e0258145.","journal-title":"PLoS ONE"},{"issue":"12","key":"1587_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114881","volume":"9","author":"ND Vaziri","year":"2014","unstructured":"Vaziri ND, Liu SM, Lau WL, et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS ONE. 2014;9(12):e114881.","journal-title":"PLoS ONE"},{"key":"1587_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072382","author":"H Sheyholislami","year":"2021","unstructured":"Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. Nutrients. 2021;13(7):2382.\u00a0https:\/\/doi.org\/10.3390\/nu13072382.","journal-title":"Nutrients"},{"key":"1587_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040805","author":"Z Ebrahim","year":"2022","unstructured":"Ebrahim Z, Proost S, Tito RY, et al. The effect of \u00df-glucan prebiotic on kidney function, uremic toxins and gut microbiome in stage 3 to 5 chronic kidney disease (CKD) predialysis participants: a randomized controlled trial. Nutrients. 2022;14(4):805. https:\/\/doi.org\/10.3390\/nu14040805.","journal-title":"Nutrients"},{"issue":"3","key":"1587_CR159","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.jrn.2014.09.002","volume":"25","author":"YA Salmean","year":"2015","unstructured":"Salmean YA, Segal MS, Palii SP, et al. Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients. J Ren Nutr. 2015;25(3):316\u201320.","journal-title":"J Ren Nutr"},{"issue":"1","key":"1587_CR160","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/ndt\/gfp414","volume":"25","author":"BK Meijers","year":"2010","unstructured":"Meijers BK, De Preter V, Verbeke K, et al. P-cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant. 2010;25(1):219\u201324.","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-019-0343-x","volume":"16","author":"HT Khosroshahi","year":"2019","unstructured":"Khosroshahi HT, Abedi B, Ghojazadeh M,\u00a0et al. Effects of fermentable high fiber diet supplementation on gut derived and conventional nitrogenous product in patients on maintenance hemodialysis: a randomized controlled trial. Nutr Metab (Lond). 2019;16:18.","journal-title":"Nutr Metab (Lond)"},{"issue":"4","key":"1587_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153893","volume":"11","author":"R Poesen","year":"2016","unstructured":"Poesen R, Evenepoel P, de Loor H, et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS ONE. 2016;11(4):e0153893.","journal-title":"PLoS ONE"},{"issue":"11","key":"1587_CR163","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ndt\/gfy171","volume":"34","author":"CI Ramos","year":"2019","unstructured":"Ramos CI, Armani RG, Canziani MEF, et al. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant. 2019;34(11):1876\u201384.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1587_CR164","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ndt\/gfaa335","volume":"37","author":"RG Armani","year":"2021","unstructured":"Armani RG, Carvalho AB, Ramos CI, et al. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrol Dial Transplant. 2021;37(1):85\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1587_CR165","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.jrn.2020.10.003","volume":"31","author":"A Biruete","year":"2021","unstructured":"Biruete A, Cross TL, Allen JM, et al. Effect of dietary inulin supplementation on the gut microbiota composition and derived metabolites of individuals undergoing hemodialysis: a pilot study. J Ren Nutr. 2021;31(5):512\u201322.","journal-title":"J Ren Nutr"},{"issue":"9","key":"1587_CR166","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2215\/CJN.00490114","volume":"9","author":"TL Sirich","year":"2014","unstructured":"Sirich TL, Plummer NS, Gardner CD, et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol. 2014;9(9):1603\u201310.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"1587_CR167","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1039\/C8FO01876F","volume":"9","author":"M Esgalhado","year":"2018","unstructured":"Esgalhado M, Kemp JA, Azevedo R, et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial. Food Funct. 2018;9(12):6508\u201316.","journal-title":"Food Funct"},{"issue":"3","key":"1587_CR168","doi-asserted-by":"publisher","first-page":"445","DOI":"10.34067\/KID.0006132020","volume":"2","author":"DS Raj","year":"2021","unstructured":"Raj DS, Sohn MB, Charytan DM, et al. The microbiome and p-inulin in hemodialysis: a feasibility study. Kidney360. 2021;2(3):445\u201355.","journal-title":"Kidney360"},{"issue":"5","key":"1587_CR169","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/ajcn\/nqz337","volume":"111","author":"L Li","year":"2020","unstructured":"Li L, Xiong Q, Zhao J, et al. Inulin-type fructan intervention restricts the increase in gut microbiome-generated indole in patients with peritoneal dialysis: a randomized crossover study. Am J Clin Nutr. 2020;111(5):1087\u201399.","journal-title":"Am J Clin Nutr"},{"key":"1587_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020646","author":"LS de Andrade","year":"2021","unstructured":"de Andrade LS, Sard\u00e1 FAH, Pereira NBF, et al. Effect of unripe banana flour on gut-derived uremic toxins in individuals undergoing peritoneal dialysis: a randomized, double-blind, placebo-controlled, crossover trial. Nutrients. 2021;13(2):646. https:\/\/doi.org\/10.3390\/nu13020646.","journal-title":"Nutrients"},{"issue":"8","key":"1587_CR171","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ekir.2020.05.023","volume":"5","author":"B Gao","year":"2020","unstructured":"Gao B, Alonzo-Palma N, Brooks B, et al. A pilot study on the effect of prebiotic on host-microbial co-metabolism in peritoneal dialysis patients. Kidney Int Rep. 2020;5(8):1309\u201315.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1587_CR172","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1039\/C9FO02939G","volume":"11","author":"M Esgalhado","year":"2020","unstructured":"Esgalhado M, Kemp JA, Paiva BR, et al. Resistant starch type-2 enriched cookies modulate uremic toxins and inflammation in hemodialysis patients: a randomized, double-blind, crossover and placebo-controlled trial. Food Funct. 2020;11(3):2617\u201325.","journal-title":"Food Funct"},{"issue":"8","key":"1587_CR173","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506\u201314.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1587_CR174","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2146\/ajhp090168","volume":"67","author":"NT Williams","year":"2010","unstructured":"Williams NT. Probiotics. Am J Health Syst Pharm. 2010;67(6):449\u201358.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"1587_CR175","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1017\/S0007114513002560","volume":"111","author":"SE Power","year":"2014","unstructured":"Power SE, O'Toole PW, Stanton C, et al. Intestinal microbiota, diet and health. Br J Nutr. 2014;111(3):387\u2013402.","journal-title":"Br J Nutr"},{"issue":"26","key":"1587_CR176","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1021\/acs.jafc.1c01547","volume":"69","author":"H Huang","year":"2021","unstructured":"Huang H, Li K, Lee Y, et al. Preventive effects of Lactobacillus mixture against chronic kidney disease progression through enhancement of beneficial bacteria and downregulation of gut-derived uremic toxins. J Agric Food Chem. 2021;69(26):7353\u201366.","journal-title":"J Agric Food Chem"},{"issue":"4","key":"1587_CR177","first-page":"1130","volume":"45","author":"TH Lee","year":"2020","unstructured":"Lee TH, Park D, Kim YJ, et al. Lactobacillus salivarius BP121 prevents cisplatin-induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p-cresol sulfate via alleviating dysbiosis. Int J Mol Med. 2020;45(4):1130\u201340.","journal-title":"Int J Mol Med"},{"issue":"6","key":"1587_CR178","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00446-22","volume":"7","author":"GA Stuivenberg","year":"2022","unstructured":"Stuivenberg GA, Chmiel JA, Akouris PP, et al. Probiotic bifidobacteria mitigate the deleterious effects of para-cresol in a Drosophila melanogaster toxicity model. mSphere. 2022;7(6):e0044622.","journal-title":"mSphere"},{"issue":"1","key":"1587_CR179","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2185034","volume":"15","author":"D Merenstein","year":"2023","unstructured":"Merenstein D, Pot B, Leyer G, et al. Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes. 2023;15(1):2185034.","journal-title":"Gut Microbes"},{"key":"1587_CR180","doi-asserted-by":"crossref","unstructured":"Kalidindi RK, Reddy CP, Pv K, et al. The efficacy and safety of probiotic combinations Lobun Forte\u00ae versus Renadyl\u00ae in patients with chronic kidney disease: a comparative, phase IV, randomized, open-label, active-controlled, parallel study. Cureus. 2024;16(8):e67987.","DOI":"10.7759\/cureus.67987"},{"key":"1587_CR181","doi-asserted-by":"crossref","unstructured":"Eidi F, Poor-Reza Gholi F, Ostadrahimi A, et al. Effect of Lactobacillus rhamnosus on serum uremic toxins (phenol and p-cresol) in hemodialysis patients: a double blind randomized clinical trial. Clin Nutr ESPEN. 2018;28:158\u201364.","DOI":"10.1016\/j.clnesp.2018.08.010"},{"key":"1587_CR182","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jff.2018.05.018","volume":"46","author":"A Barros","year":"2018","unstructured":"Barros A, Borges NA, Nakao LS, et al. Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: a double-blind, randomized, placebo-controlled trial. J Function Foods. 2018;46:378\u201383.","journal-title":"J Function Foods."},{"key":"1587_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/nu14081637","author":"A De Mauri","year":"2022","unstructured":"De Mauri A, Carrera D, Bagnati M, et al. Probiotics-supplemented low-protein diet for microbiota modulation in patients with advanced chronic kidney disease (ProLowCKD): results from a placebo-controlled randomized trial. Nutrients. 2022;14(8):1637. https:\/\/doi.org\/10.3390\/nu14081637.","journal-title":"Nutrients"},{"issue":"2","key":"1587_CR184","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000189334","volume":"74","author":"M Hida","year":"1996","unstructured":"Hida M, Aiba Y, Sawamura S, et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74(2):349\u201355.","journal-title":"Nephron"},{"issue":"4","key":"1587_CR185","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3345\/kjp.2013.56.4.159","volume":"56","author":"HS Hyun","year":"2013","unstructured":"Hyun HS, Paik KH, Cho HY. P-cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J Pediatr. 2013;56(4):159\u201364.","journal-title":"Korean J Pediatr"},{"key":"1587_CR186","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/568571","volume":"2014","author":"R Natarajan","year":"2014","unstructured":"Natarajan R, Pechenyak B, Vyas U, et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Res Int. 2014;2014:568571.","journal-title":"BioMed Res Int"},{"issue":"1","key":"1587_CR187","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.jrn.2017.06.010","volume":"28","author":"NA Borges","year":"2018","unstructured":"Borges NA, Carmo FL, Stockler-Pinto MB, et al. Probiotic supplementation in chronic kidney disease: a double-blind, randomized, placebo-controlled trial. J Ren Nutr. 2018;28(1):28\u201336.","journal-title":"J Ren Nutr"},{"issue":"2","key":"1587_CR188","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.jrn.2020.07.002","volume":"31","author":"PS Lim","year":"2021","unstructured":"Lim PS, Wang HF, Lee MC, et al. The efficacy of Lactobacillus-containing probiotic supplementation in hemodialysis patients: a randomized, double-blind, placebo-controlled trial. J Ren Nutr. 2021;31(2):189\u201398.","journal-title":"J Ren Nutr"},{"issue":"11","key":"1587_CR189","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41575-020-0344-2","volume":"17","author":"KS Swanson","year":"2020","unstructured":"Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687\u2013701.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1587_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/nu9091021","author":"P Markowiak","year":"2017","unstructured":"Markowiak P, \u015ali\u017cewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021.\u00a0https:\/\/doi.org\/10.3390\/nu9091021.","journal-title":"Nutrients"},{"key":"1587_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010114","author":"CY Yang","year":"2021","unstructured":"Yang CY, Chen TW, Lu WL, et al. Synbiotics alleviate the gut indole load and dysbiosis in chronic kidney disease. Cells. 2021;10(1):114. https:\/\/doi.org\/10.3390\/cells10010114.","journal-title":"Cells"},{"issue":"5","key":"1587_CR192","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000488947","volume":"47","author":"Y Iwashita","year":"2018","unstructured":"Iwashita Y, Ohya M, Yashiro M, et al. Dietary changes involving Bifidobacterium longum and other nutrients delays chronic kidney disease progression. Am J Nephrol. 2018;47(5):325\u201332.","journal-title":"Am J Nephrol"},{"issue":"4","key":"1587_CR193","doi-asserted-by":"publisher","first-page":"240","DOI":"10.7326\/M18-0343","volume":"169","author":"A Bafeta","year":"2018","unstructured":"Bafeta A, Koh M, Riveros C, et al. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med. 2018;169(4):240\u20137.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1587_CR194","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.numecd.2014.04.007","volume":"24","author":"B Guida","year":"2014","unstructured":"Guida B, German\u00f2 R, Trio R, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis. 2014;24(9):1043\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"1587_CR195","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2215\/CJN.05240515","volume":"11","author":"M Rossi","year":"2016","unstructured":"Rossi M, Johnson DW, Morrison M, et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin J Am Soc Nephrol. 2016;11(2):223\u201331.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1587_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/nu14183804","author":"A Saxena","year":"2022","unstructured":"Saxena A, Srinivasa S, Veerappan I, et al. Enzobiotics: a novel therapy for the elimination of uremic toxins in patients with CKD (EETOX study): a multicenter double-blind randomized controlled trial. Nutrients. 2022;14(18):3804. https:\/\/doi.org\/10.3390\/nu14183804.","journal-title":"Nutrients"},{"issue":"2","key":"1587_CR197","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/j.jrn.2022.07.008","volume":"33","author":"M Mitrovi\u0107","year":"2023","unstructured":"Mitrovi\u0107 M, Stankovi\u0107-Popovi\u0107 V, Tolina\u010dki M, et al. The impact of synbiotic treatment on the levels of gut-derived uremic toxins, inflammation, and gut microbiome of chronic kidney disease patients: a randomized trial. J Ren Nutr. 2023;33(2):278\u201388.","journal-title":"J Ren Nutr"},{"key":"1587_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081383","author":"T Kuskunov","year":"2023","unstructured":"Kuskunov T, Tilkiyan E, Doykov D, et al. The effect of synbiotic supplementation on uremic toxins, oxidative stress, and inflammation in hemodialysis patients: results of an uncontrolled prospective single-arm study. Medicina (Kaunas). 2023;59(8):1383. https:\/\/doi.org\/10.3390\/medicina59081383.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"1587_CR199","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17425255.2024.2409257","volume":"21","author":"AR Al-Dajani","year":"2025","unstructured":"Al-Dajani AR, Kiang TKL. A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p-cresol sulfate, p-cresol glucuronide, indoxyl sulfate, and indoxyl glucuronide in HepaRG culture medium and the demonstration of mefenamic acid as a potent and selective detoxifying agent. Expert Opin Drug Metab Toxicol. 2025;21(1):81\u201393.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1587_CR200","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/ndt\/gfq624","volume":"26","author":"I Nakabayashi","year":"2011","unstructured":"Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant. 2011;26(3):1094\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1587_CR201","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.foodres.2018.08.024","volume":"116","author":"R Lopes","year":"2019","unstructured":"Lopes R, Theodoro JMV, da Silva BP, et al. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial. Food Res Int. 2019;116:241\u20138.","journal-title":"Food Res Int"},{"key":"1587_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/nu16121852","author":"HG L\u00facio","year":"2024","unstructured":"L\u00facio HG, Lopes RCSO, Gomes\u00a0 MJC, et al. A symbiotic meal containing extruded sorghum and probiotic (Bifidobacterium longum) ameliorated intestinal health markers in individuals with chronic kidney disease: a secondary analysis of a subsample from a previous randomized and controlled clinical trial. Nutrients. 2024;16(12):1852.\u00a0\u00a0https:\/\/doi.org\/10.3390\/nu16121852.","journal-title":"Nutrients"},{"key":"1587_CR203","doi-asserted-by":"publisher","unstructured":"Rocchetti MT, Cosola C, di Bari I, et al. Efficacy of divinylbenzenic resin in removing indoxyl sulfate and p-cresol sulfate in hemodialysis patients: results from an in vitro study and an in vivo pilot trial (xuanro4-Nature 3.2). Toxins (Basel). 2020;12(3):170. https:\/\/doi.org\/10.3390\/toxins112(3):170.2030170.","DOI":"10.3390\/toxins112(3):170.2030170"},{"key":"1587_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13050334","author":"C Cosola","year":"2021","unstructured":"Cosola C, Rocchetti MT, di Bari I, et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins (Basel). 2021;13(5):334.\u00a0https:\/\/doi.org\/10.3390\/toxins13050334.","journal-title":"Toxins (Basel)"},{"key":"1587_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/nu13124481","author":"C McFarlane","year":"2021","unstructured":"McFarlane C, Krishnasamy R, Stanton T, et al. Synbiotics easing renal failure by improving gut microbiology II (SYNERGY II): a feasibility randomized controlled trial. Nutrients. 2021;13(12):4481.\u00a0https:\/\/doi.org\/10.3390\/nu13124481.","journal-title":"Nutrients"},{"key":"1587_CR206","doi-asserted-by":"crossref","unstructured":"Panza F, Duranti D, Chiara R, et al. Short-term effects of pre\/probiotics on p-Cresol and indoxyl-sulphate serum concentrations during the various stages of chronic kidney disease. Arch Renal Dis Manage. 2017;3(1):001\u2013005.","DOI":"10.17352\/2455-5495.000017"},{"key":"1587_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061986","author":"T Gryp","year":"2020","unstructured":"Gryp T, Huys GRB, Joossens M, et al. Isolation and quantification of uremic toxin precursor-generating gut bacteria in chronic kidney disease patients. Int J Mol Sci. 2020;21(6):1986. https:\/\/doi.org\/10.3390\/ijms21061986.","journal-title":"Int J Mol Sci"},{"key":"1587_CR208","doi-asserted-by":"publisher","DOI":"10.1093\/femsec\/fiy125","author":"Y Saito","year":"2018","unstructured":"Saito Y, Sato T, Nomoto K, et al. Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiol Ecol. 2018;94(9):fiy125. https:\/\/doi.org\/10.1093\/femsec\/fiy125.","journal-title":"FEMS Microbiol Ecol"},{"issue":"11","key":"1587_CR209","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.34067\/KID.0003942020","volume":"1","author":"C Kimber","year":"2020","unstructured":"Kimber C, Zhang S, Johnson C, et al. Randomized, placebo-controlled trial of rifaximin therapy for lowering gut-derived cardiovascular toxins and inflammation in CKD. Kidney360. 2020;1(11):1206\u201316.","journal-title":"Kidney360"},{"issue":"11","key":"1587_CR210","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/ndt\/gfx029","volume":"32","author":"L Nazzal","year":"2017","unstructured":"Nazzal L, Roberts J, Singh P, et al. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrol Dial Transplant. 2017;32(11):1809\u201317.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1587_CR211","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.ekir.2021.05.014","volume":"6","author":"L Nazzal","year":"2021","unstructured":"Nazzal L, Soiefer L, Chang M, et al. Effect of vancomycin on the gut microbiome and plasma concentrations of gut-derived uremic solutes. Kidney Int Rep. 2021;6(8):2122\u201333.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"1587_CR212","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jac\/dkw383","volume":"72","author":"S Isaac","year":"2017","unstructured":"Isaac S, Scher JU, Djukovic A, et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. J Antimicrob Chemother. 2017;72(1):128\u201336.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1587_CR213","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.amjmed.2024.03.024","volume":"137","author":"M Cymbal","year":"2024","unstructured":"Cymbal M, Chatterjee A, Baggott B, et al. Management of Clostridioides difficile infection: diagnosis, treatment, and future perspectives. Am J Med. 2024;137(7):571\u20136.","journal-title":"Am J Med"},{"issue":"5","key":"1587_CR214","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jiac.2019.12.020","volume":"26","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Konishi H, Aoki K, et al. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother. 2020;26(5):483\u201391.","journal-title":"J Infect Chemother"},{"key":"1587_CR215","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914621","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Bi Z, Hamilton MJ, et al. P-cresol sulfate is a sensitive urinary marker of fecal microbiota transplantation and antibiotics treatments in human patients and mouse models. Int J Mol Sci. 2023;24(19):14621. https:\/\/doi.org\/10.3390\/ijms241914621.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1587_CR216","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9):667\u201370.","journal-title":"J Antibiot (Tokyo)"},{"key":"1587_CR217","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092211","author":"W Fusco","year":"2023","unstructured":"Fusco W, Lorenzo MB, Cintoni M, et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023;15(9):2211.\u00a0https:\/\/doi.org\/10.3390\/nu15092211.","journal-title":"Nutrients"},{"issue":"2","key":"1587_CR218","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","volume":"146","author":"D Xu","year":"2014","unstructured":"Xu D, Gao J, III Gillilland M, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484-96.e4.","journal-title":"Gastroenterology"},{"issue":"6","key":"1587_CR219","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1016\/j.clnu.2021.01.045","volume":"40","author":"HY Chen","year":"2021","unstructured":"Chen HY, Sun CY, Lee CC, et al. Ketoanalogue supplements reduce mortality in patients with pre-dialysis advanced diabetic kidney disease: a nationwide population-based study. Clin Nutr. 2021;40(6):4149\u201360.","journal-title":"Clin Nutr"},{"issue":"1","key":"1587_CR220","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ki.1982.131","volume":"22","author":"WE Mitch","year":"1982","unstructured":"Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int. 1982;22(1):48\u201353.","journal-title":"Kidney Int"},{"issue":"3","key":"1587_CR221","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11255-015-1170-2","volume":"48","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, Tang Y, Yang L, et al. Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(3):409\u201318.","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"1587_CR222","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1440-1797.2009.01115.x","volume":"14","author":"JH Chang","year":"2009","unstructured":"Chang JH, Kim DK, Park JT, et al. Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrology. 2009;14(8):750\u20137.","journal-title":"Nephrology"},{"key":"1587_CR223","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194020","author":"CL Yen","year":"2022","unstructured":"Yen CL, Fan PC, Chen JJ, et al. Ketoanalogues supplemental low protein diet safely decreases short-term risk of dialysis among CKD stage 4 patients. Nutrients. 2022;14(19):4020. https:\/\/doi.org\/10.3390\/nu14194020.","journal-title":"Nutrients"},{"key":"1587_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/nu12113358","author":"CL Yen","year":"2020","unstructured":"Yen CL, Fan PC, Lee CC, et al. Advanced chronic kidney disease with low and very low GFR: can a low-protein diet supplemented with ketoanalogues delay dialysis? Nutrients. 2020;12(11):3358. https:\/\/doi.org\/10.3390\/nu12113358.","journal-title":"Nutrients"},{"issue":"1","key":"1587_CR225","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-019-1856-9","volume":"17","author":"M Wang","year":"2019","unstructured":"Wang M, Xu H, Chong Lee Shin OL, et al. Compound \u03b1-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways. J Transl Med. 2019;17(1):122.","journal-title":"J Transl Med"},{"key":"1587_CR226","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051312","author":"G Chang","year":"2023","unstructured":"Chang G, Shih HM, Pan CF, et al. Effect of low protein diet supplemented with ketoanalogs on endothelial function and protein-bound uremic toxins in patients with chronic kidney disease. Biomedicines. 2023;11(5):1312. https:\/\/doi.org\/10.3390\/biomedicines11051312.","journal-title":"Biomedicines"},{"key":"1587_CR227","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091424","author":"BR Di Iorio","year":"2019","unstructured":"Di Iorio BR, Rocchetti MT, De Angelis M, et al. Nutritional therapy modulates intestinal microbiota and reduces serum levels of total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease (Medika study). J Clin Med. 2019;8(9):1424. https:\/\/doi.org\/10.3390\/jcm8091424.","journal-title":"J Clin Med"},{"key":"1587_CR228","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040840","author":"MT Rocchetti","year":"2021","unstructured":"Rocchetti MT, Di Iorio BR, Vacca M, et al. Ketoanalogs\u2019 effects on intestinal microbiota modulation and uremic toxins serum levels in chronic kidney disease (Medika2 study). J Clin Med. 2021;10(4):840. https:\/\/doi.org\/10.3390\/jcm10040840.","journal-title":"J Clin Med"},{"key":"1587_CR229","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ad6dc7","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yin R, Tian Y, et al. Curcumin nanopreparations: recent advance in preparation and application. Biomed Mater. 2024;19:052009. https:\/\/doi.org\/10.1088\/1748-605X\/ad6dc7.","journal-title":"Biomed Mater"},{"issue":"1","key":"1587_CR230","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14200\/jrm.2017.6.0101","volume":"6","author":"S Toden","year":"2017","unstructured":"Toden S, Goel A. The holy grail of curcumin and its efficacy in various diseases: is bioavailability truly a big concern? J Restor Med. 2017;6(1):27\u201336.","journal-title":"J Restor Med"},{"key":"1587_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156144","volume":"164","author":"MJ Dehzad","year":"2023","unstructured":"Dehzad MJ, Ghalandari H, Nouri M, et al. Antioxidant and anti-inflammatory effects of curcumin\/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Cytokine. 2023;164:156144.","journal-title":"Cytokine"},{"key":"1587_CR232","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clnesp.2017.09.006","volume":"22","author":"F Samadian","year":"2017","unstructured":"Samadian F, Dalili N, Poor-Reza Gholi, et al. Evaluation of Curcumin\u2019s effect on inflammation in hemodialysis patients. Clin Nutr ESPEN. 2017;22:19\u201323.","journal-title":"Clin Nutr ESPEN"},{"key":"1587_CR233","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030496","author":"D Mafra","year":"2019","unstructured":"Mafra D, Borges N, Alvarenga L, et al. Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. Nutrients. 2019;11(3):496. https:\/\/doi.org\/10.3390\/nu11030496.","journal-title":"Nutrients"},{"issue":"10","key":"1587_CR234","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185999","volume":"12","author":"M Ohno","year":"2017","unstructured":"Ohno M, Nishida A, Sugitani Y, et al. Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS ONE. 2017;12(10):e0185999.","journal-title":"PLoS ONE"},{"issue":"4","key":"1587_CR235","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/0049825031000065197","volume":"33","author":"M Vietri","year":"2003","unstructured":"Vietri M, Pietrabissa A, Mosca F, et al. Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. Xenobiotica. 2003;33(4):357\u201363.","journal-title":"Xenobiotica"},{"key":"1587_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115553","volume":"425","author":"Y Rong","year":"2021","unstructured":"Rong Y, Kiang TKL. Characterization of human sulfotransferases catalyzing the formation of p-cresol sulfate and identification of mefenamic acid as a potent metabolism inhibitor and potential therapeutic agent for detoxification. Toxicol Appl Pharmacol. 2021;425:115553.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1587_CR237","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.etp.2016.08.006","volume":"69","author":"HR Momeni","year":"2017","unstructured":"Momeni HR, Eskandari N. Effect of curcumin on kidney histopathological changes, lipid peroxidation and total antioxidant capacity of serum in sodium arsenite-treated mice. Exp Toxicol Pathol. 2017;69(2):93\u20137.","journal-title":"Exp Toxicol Pathol"},{"issue":"10","key":"1587_CR238","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1080\/0886022X.2016.1229996","volume":"38","author":"Y Topcu-Tarladacalisir","year":"2016","unstructured":"Topcu-Tarladacalisir Y, Sapmaz-Metin M, Karaca T. Curcumin counteracts cisplatin-induced nephrotoxicity by preventing renal tubular cell apoptosis. Ren Fail. 2016;38(10):1741\u20138.","journal-title":"Ren Fail"},{"issue":"1","key":"1587_CR239","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2444393","volume":"47","author":"P An","year":"2025","unstructured":"An P, Li X, Zhao Y, et al. Curcumin alleviates renal fibrosis in chronic kidney disease by targeting the circ_0008925-related pathway. Ren Fail. 2025;47(1):2444393.","journal-title":"Ren Fail"},{"issue":"7","key":"1587_CR240","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.7150\/ijms.72646","volume":"19","author":"CW Wei","year":"2022","unstructured":"Wei CW, Wu TK, Wu SC, et al. Curcumin enhances p-cresyl sulfate-induced cytotoxic effects on renal tubular cells. Int J Med Sci. 2022;19(7):1138\u201346.","journal-title":"Int J Med Sci"},{"issue":"14","key":"1587_CR241","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1002\/jsfa.11372","volume":"101","author":"ME Abd El-Hack","year":"2021","unstructured":"Abd El-Hack ME, EI-Saadony MT, Swelum AA, et al. Curcumin, the active substance of turmeric: its effects on health and ways to improve its bioavailability. J Sci Food Agric. 2021;101(14):5747\u201362.","journal-title":"J Sci Food Agric"},{"key":"1587_CR242","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020135","author":"M Uro\u0161evi\u0107","year":"2022","unstructured":"Uro\u0161evi\u0107 M, Nikoli\u0107 L, Gaji\u0107 I,\u00a0et al. Curcumin: biological activities and modern pharmaceutical forms. Antibiotics. 2022;11(2):135. https:\/\/doi.org\/10.3390\/antibiotics11020135.","journal-title":"Antibiotics"},{"issue":"6","key":"1587_CR243","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s11255-020-02760-z","volume":"53","author":"RT Salarolli","year":"2021","unstructured":"Salarolli RT, Alvarenga L, Cardozo LFMF, et al. Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study. Int Urol Nephrol. 2021;53(6):1231\u20138.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"1587_CR244","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.clnu.2020.03.007","volume":"39","author":"L Alvarenga","year":"2020","unstructured":"Alvarenga L, Salarolli R, Cardozo LFMF, et al. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: a pilot randomized, double-blind, controlled study. Clin Nutr. 2020;39(12):3594\u2013600.","journal-title":"Clin Nutr"},{"key":"1587_CR245","doi-asserted-by":"publisher","unstructured":"Pivari F, Mingione A, Piazzini G, et al. Curcumin supplementation (Meriva\u00ae) modulates inflammation, lipid peroxidation and gut microbiota composition in chronic kidney disease. Nutrients. 2022;14(1). https:\/\/doi.org\/10.3390\/nu14010231.","DOI":"10.3390\/nu14010231"},{"key":"1587_CR246","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.clnesp.2023.11.015","volume":"59","author":"D Reis","year":"2024","unstructured":"Reis D, Alvarenga L, Cardozo LFMF, et al. Can curcumin supplementation break the vicious cycle of inflammation, oxidative stress, and uremia in patients undergoing peritoneal dialysis? Clin Nutr ESPEN. 2024;59:96\u2013106.","journal-title":"Clin Nutr ESPEN"},{"issue":"5","key":"1587_CR247","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/MPG.0000000000000285","volume":"58","author":"IE Fran\u00e7ois","year":"2014","unstructured":"Fran\u00e7ois IE, Lescroart O, Veraverbeke WS, et al. Effects of wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal parameters in healthy preadolescent children. J Pediatr Gastroenterol Nutr. 2014;58(5):647\u201353.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1587_CR248","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.foodres.2018.03.004","volume":"107","author":"R Lopes","year":"2018","unstructured":"Lopes R, de Lima SLS, da Silva BP, et al. Evaluation of the health benefits of consumption of extruded tannin sorghum with unfermented probiotic milk in individuals with chronic kidney disease. Food Res Int. 2018;107:629\u201338.","journal-title":"Food Res Int"},{"issue":"5","key":"1587_CR249","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ndt\/gfx203","volume":"33","author":"BR Di Iorio","year":"2018","unstructured":"Di Iorio BR, Marzocco S, Bellasi A, et al. Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease. Nephrol Dial Transplant. 2018;33(5):804\u201313.","journal-title":"Nephrol Dial Transplant"},{"issue":"1\u20132","key":"1587_CR250","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0021-9673(03)00394-7","volume":"993","author":"M Jaworska","year":"2003","unstructured":"Jaworska M, Szuli\u0144ska Z, Wilk M. Development of a capillary electrophoretic method for the analysis of amino acids containing tablets. J Chromatogr A. 2003;993(1\u20132):165\u201372.","journal-title":"J Chromatogr A"},{"issue":"2","key":"1587_CR251","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/j.jrn.2004.01.008","volume":"14","author":"S Prakash","year":"2004","unstructured":"Prakash S, Pande DP, Sharma S, et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. J Ren Nutr. 2004;14(2):89\u201396.","journal-title":"J Ren Nutr"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01587-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:01:57Z","timestamp":1766059317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":251,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01587-0","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20171694","asserted-by":"subject"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Puja Dhungana, Andrew Dam, and Tony K.L. Kiang have no conflicts of interest that are directly relevant to the content of this article. Tony\u00a0Kiang is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      .\u00a0Tony\u00a0Kiang was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The literature data reviewed in this paper are available on public scientific databases.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"TK envisioned the research; PD carried out the literature search; PD and AD extracted the relevant data independently and TK verified the extracted data; PD wrote the first draft of the manuscript; TK extensively edited and prepared the final submission. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}